630 related articles for article (PubMed ID: 9517654)
1. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine.
Egan LJ; Sandborn WJ; Tremaine WJ
Am J Gastroenterol; 1998 Mar; 93(3):442-8. PubMed ID: 9517654
[TBL] [Abstract][Full Text] [Related]
2. Cyclosporine and 6-mercaptopurine for active, refractory Crohn's colitis in children.
Mahdi G; Israel DM; Hassall E
Am J Gastroenterol; 1996 Jul; 91(7):1355-9. PubMed ID: 8677994
[TBL] [Abstract][Full Text] [Related]
3. [Cyclosporin A therapy in steroid-refractory patients with chronic inflammatory bowel diseases].
Dejaco C; Gasché C; Reinisch W; Moser G; Novacek G; Tillinger W; Vogelsang H; Gangl A
Wien Klin Wochenschr; 1998 Sep; 110(16):579-84. PubMed ID: 9782579
[TBL] [Abstract][Full Text] [Related]
4. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease.
Sandborn WJ
Am J Gastroenterol; 1997 May; 92(5):876-9. PubMed ID: 9149205
[TBL] [Abstract][Full Text] [Related]
5. Optimum duration of treatment with 6-mercaptopurine for Crohn's disease.
Kim PS; Zlatanic J; Korelitz BI; Gleim GW
Am J Gastroenterol; 1999 Nov; 94(11):3254-7. PubMed ID: 10566725
[TBL] [Abstract][Full Text] [Related]
6. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A.
Hanauer SB; Smith MB
Am J Gastroenterol; 1993 May; 88(5):646-9. PubMed ID: 8480725
[TBL] [Abstract][Full Text] [Related]
7. Review article: Medical therapy for fistulizing Crohn's disease.
Bressler B; Sands BE
Aliment Pharmacol Ther; 2006 Nov; 24(9):1283-93. PubMed ID: 17059510
[TBL] [Abstract][Full Text] [Related]
8. Combination of cyclosporine, azathioprine and prednisolone for perianal fistulas in Crohn's disease.
Hinterleitner TA; Petritsch W; Aichbichler B; Fickert P; Ranner G; Krejs GJ
Z Gastroenterol; 1997 Aug; 35(8):603-8. PubMed ID: 9297775
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcome of Crohn's disease treated with infliximab.
Arslan S; Kav T; Besisik F; Kaymakoglu S; Pinarbasi B; Tözün N; Hamzaoglu HO; Duman D; Ulker A; Parlak E; Palabiyikoglu M; Dökmeci A
Hepatogastroenterology; 2003; 50(52):952-6. PubMed ID: 12845957
[TBL] [Abstract][Full Text] [Related]
10. Clinical response does not correlate with intestinal or blood cyclosporine concentrations in patients with Crohn's disease treated with high-dose oral cyclosporine.
Sandborn WJ; Tremaine WJ; Lawson GM
Am J Gastroenterol; 1996 Jan; 91(1):37-43. PubMed ID: 8561141
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
Hlavaty T; Pierik M; Henckaerts L; Ferrante M; Joossens S; van Schuerbeek N; Noman M; Rutgeerts P; Vermeire S
Aliment Pharmacol Ther; 2005 Oct; 22(7):613-26. PubMed ID: 16181301
[TBL] [Abstract][Full Text] [Related]
12. Thalidomide in luminal and fistulizing Crohn's disease resistant to standard therapies.
Plamondon S; Ng SC; Kamm MA
Aliment Pharmacol Ther; 2007 Mar; 25(5):557-67. PubMed ID: 17305756
[TBL] [Abstract][Full Text] [Related]
13. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
14. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506).
Fellermann K; Ludwig D; Stahl M; David-Walek T; Stange EF
Am J Gastroenterol; 1998 Oct; 93(10):1860-6. PubMed ID: 9772045
[TBL] [Abstract][Full Text] [Related]
15. Short-term efficacy and long-term outcome of cyclosporine treatment in patients with severe ulcerative colitis.
Wenzl HH; Petritsch W; Aichbichler BW; Hinterleitner TA; Fleischmann G; Krejs GJ
Z Gastroenterol; 1998 Apr; 36(4):287-93. PubMed ID: 9612926
[TBL] [Abstract][Full Text] [Related]
16. Combining infliximab with 6-mercaptopurine/azathioprine for fistula therapy in Crohn's disease.
Ochsenkühn T; Göke B; Sackmann M
Am J Gastroenterol; 2002 Aug; 97(8):2022-5. PubMed ID: 12190171
[TBL] [Abstract][Full Text] [Related]
17. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients.
Ricart E; Panaccione R; Loftus EV; Tremaine WJ; Sandborn WJ
Am J Gastroenterol; 2001 Mar; 96(3):722-9. PubMed ID: 11280541
[TBL] [Abstract][Full Text] [Related]
18. High-dose intravenous cyclosporine in steroid refractory attacks of inflammatory bowel disease.
Hermida-Rodriguez C; Cantero Perona J; Garcia-Valriberas R; Pajares Garcia JM; Mate-Jimenez J
Hepatogastroenterology; 1999; 46(28):2265-8. PubMed ID: 10521978
[TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide pulse therapy followed by azathioprine or methotrexate induces long-term remission in patients with steroid-refractory Crohn's disease.
Schmidt C; Wittig BM; Moser C; Zeitz M; Stallmach A
Aliment Pharmacol Ther; 2006 Jul; 24(2):343-50. PubMed ID: 16842461
[TBL] [Abstract][Full Text] [Related]
20. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
Gao Q; Hogezand RA; Lamers CB; Verspaget HW
Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
